Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine and MET for Tobacco Use Disorder
NCT05796791Phase 1Completed
- Sponsor
- Medical University of South Carolina
- Start
- May 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ketamine in Tobacco Use Disorder (TUD), sponsored by Medical University of South Carolina. Primary endpoint: Feasibility of Ketamine Treatment for Tobacco Use Disorder at 8 weeks. Started May 2023; status: completed.
02
Drugs
ketamine
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT05796791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05796791.